ANI Pharmaceuticals (ANIP) Revenue & Revenue Breakdown
ANI Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$486.82M
Latest Revenue (Q)
$138.04M
Main Segment (Y)
Sales of generic pharmaceutical products
Main Geography (Y)
UNITED STATES
ANI Pharmaceuticals Revenue by Period
ANI Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $486.82M | 53.87% |
| 2022-12-31 | $316.38M | 46.38% |
| 2021-12-31 | $216.14M | 3.67% |
| 2020-12-31 | $208.47M | 0.93% |
| 2019-12-31 | $206.55M | 2.47% |
| 2018-12-31 | $201.58M | 13.99% |
| 2017-12-31 | $176.84M | 37.49% |
| 2016-12-31 | $128.62M | 68.53% |
| 2015-12-31 | $76.32M | 36.36% |
| 2014-12-31 | $55.97M | 86.06% |
| 2013-12-31 | $30.08M | 1207.49% |
| 2012-12-31 | $2.30M | 428.71% |
| 2011-12-31 | $435.16K | -82.41% |
| 2010-12-31 | $2.47M | 96.67% |
| 2009-12-31 | $1.26M | -66.73% |
| 2008-12-31 | $3.78M | 666.82% |
| 2007-12-31 | $493.05K | -96.59% |
| 2006-12-31 | $14.44M | 5488.76% |
| 2005-12-31 | $258.35K | 231.70% |
| 2004-12-31 | $77.89K | 18.92% |
| 2003-12-31 | $65.49K | -97.69% |
| 2002-12-31 | $2.83M | 62.18% |
| 2001-12-31 | $1.75M | 87369200.00% |
| 2000-12-31 | $2.00 | 100.00% |
| 1999-12-31 | $1.00 | -100.00% |
| 1998-12-31 | $123.06K | - |
ANI Pharmaceuticals generated $486.82M in revenue during NA 2023, up 53.87% compared to the previous quarter, and up 241.50% compared to the same period a year ago.
ANI Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $138.04M | 0.44% |
| 2024-03-31 | $137.43M | 4.39% |
| 2023-12-31 | $131.65M | -0.13% |
| 2023-09-30 | $131.83M | 13.11% |
| 2023-06-30 | $116.55M | 9.14% |
| 2023-03-31 | $106.79M | 13.32% |
| 2022-12-31 | $94.23M | 12.42% |
| 2022-09-30 | $83.82M | 13.49% |
| 2022-06-30 | $73.86M | 14.54% |
| 2022-03-31 | $64.48M | 5.82% |
| 2021-12-31 | $60.93M | 17.03% |
| 2021-09-30 | $52.06M | 7.07% |
| 2021-06-30 | $48.63M | -10.81% |
| 2021-03-31 | $54.52M | -4.77% |
| 2020-12-31 | $57.25M | 8.07% |
| 2020-09-30 | $52.98M | 9.30% |
| 2020-06-30 | $48.47M | -2.62% |
| 2020-03-31 | $49.77M | 3.77% |
| 2019-12-31 | $47.97M | -6.57% |
| 2019-09-30 | $51.34M | -5.56% |
| 2019-06-30 | $54.36M | 2.78% |
| 2019-03-31 | $52.89M | -7.41% |
| 2018-12-31 | $57.12M | 12.66% |
| 2018-09-30 | $50.70M | 7.27% |
| 2018-06-30 | $47.27M | 1.69% |
| 2018-03-31 | $46.48M | -1.70% |
| 2017-12-31 | $47.29M | -1.82% |
| 2017-09-30 | $48.16M | 7.60% |
| 2017-06-30 | $44.76M | 22.21% |
| 2017-03-31 | $36.63M | -4.13% |
| 2016-12-31 | $38.20M | -0.83% |
| 2016-09-30 | $38.52M | 22.94% |
| 2016-06-30 | $31.34M | 52.45% |
| 2016-03-31 | $20.55M | 13.97% |
| 2015-12-31 | $18.04M | -9.70% |
| 2015-09-30 | $19.97M | 2.34% |
| 2015-06-30 | $19.52M | 3.81% |
| 2015-03-31 | $18.80M | -10.64% |
| 2014-12-31 | $21.04M | 20.99% |
| 2014-09-30 | $17.39M | 161.58% |
| 2014-06-30 | $6.65M | -39.01% |
| 2014-03-31 | $10.90M | 3.48% |
| 2013-12-31 | $10.53M | 34.41% |
| 2013-09-30 | $7.84M | 27.39% |
| 2013-06-30 | $6.15M | 4141.27% |
| 2013-03-31 | $145.04K | -92.63% |
| 2012-12-31 | $1.97M | 1682.50% |
| 2012-09-30 | $110.38K | 1.47% |
| 2012-06-30 | $108.78K | -4.58% |
| 2012-03-31 | $114.00K | -0.33% |
| 2011-12-31 | $114.37K | -37.43% |
| 2011-09-30 | $182.78K | 125.65% |
| 2011-06-30 | $81.00K | 42.11% |
| 2011-03-31 | $57.00K | -60.15% |
| 2010-12-31 | $143.03K | 178.65% |
| 2010-09-30 | $51.33K | 100.00% |
| 2010-06-30 | - | -100.00% |
| 2010-03-31 | $2.28M | 114.28% |
| 2009-12-31 | $1.06M | 10040.78% |
| 2009-09-30 | $10.49K | -90.89% |
| 2009-06-30 | $115.16K | 68.30% |
| 2009-03-31 | $68.43K | -98.10% |
| 2008-12-31 | $3.61M | 4290.78% |
| 2008-09-30 | $82.21K | 217.80% |
| 2008-06-30 | $25.87K | -43.27% |
| 2008-03-31 | $45.60K | -86.15% |
| 2007-12-31 | $329.21K | - |
ANI Pharmaceuticals generated $138.04M in revenue during Q2 2024, up 0.44% compared to the previous quarter, and up 129.27% compared to the same period a year ago.
ANI Pharmaceuticals Revenue Breakdown
ANI Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Sales of generic pharmaceutical products | $269.45M | $210.12M | $143.57M | - | - |
| Sales of rare disease pharmaceutical products | $112.12M | $41.69M | - | - | - |
| Sales of established brand pharmaceutical products | $105.25M | $39.46M | - | - | - |
| Other | - | $693.00K | $1.86M | - | - |
| Sales of contract manufactured products | - | $4.30M | $3.80M | - | - |
| Royalties from licensing agreements | - | $5.37M | $11.79M | - | - |
| Product development services | - | $2.95M | $1.31M | - | - |
| Sales of branded pharmaceutical products | - | - | $47.56M | - | - |
| Other Revenues | - | - | - | $783.00K | - |
| Sales Of Branded Pharmaceutical Products | - | - | - | $47.96M | - |
| Royalties From Licensing Agreements | - | - | - | $1.40M | - |
| Product Development Services | - | - | - | $1.86M | - |
| Sales Of Generic Pharmaceutical Products | - | - | - | $147.26M | - |
| Sales Of Contract Manufactured Products | - | - | - | $6.80M | $8.10M |
| Products Development Services | - | - | - | - | $1.30M |
| Performance Obligation From Prior Period | - | - | - | - | $10.20M |
ANI Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Sales of generic pharmaceutical products (55.35%), Sales of rare disease pharmaceutical products (23.03%), and Sales of established brand pharmaceutical products (21.62%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales of rare disease pharmaceutical products | $36.94M | $71.48M | $24.30M | $16.33M | $17.59M | $12.60M | $10.20M | $1.29M | - | - | - | - | - | - | - | - | - | - | - | - |
| Sales of generic pharmaceutical products | $70.22M | $142.42M | $63.32M | $63.71M | $58.02M | $53.14M | $49.86M | $49.11M | $41.62M | - | - | - | - | - | - | - | - | - | - | - |
| Sales of contract manufactured products | - | - | - | - | $4.03M | $7.50M | $7.20M | $6.20M | $2.77M | - | - | - | - | - | - | - | - | - | - | - |
| Other | - | - | - | - | $63.00K | $164.00K | $213.00K | $253.00K | $289.00K | - | - | - | - | - | - | - | - | - | - | - |
| Product development services | - | - | - | - | $349.00K | $1.50M | $531.00K | $566.00K | $978.00K | - | - | - | - | - | - | - | - | - | - | - |
| Royalties from licensing agreements | - | - | - | - | $1.45M | $1.82M | $194.00K | $1.90M | $585.00K | - | - | - | - | - | - | - | - | - | - | - |
| Sales of established brand pharmaceutical products | - | - | - | - | $12.73M | $9.82M | $8.46M | $8.45M | - | - | - | - | - | - | - | - | - | - | - | - |
| Sales of branded pharmaceutical products | - | - | - | - | - | - | - | - | $14.69M | - | - | - | - | - | - | - | - | - | - | - |
| Other Revenues | - | - | - | - | - | - | - | - | - | $149.00K | $969.00K | $75.00K | $265.00K | $76.00K | $161.00K | $259.00K | $411.00K | - | - | - |
| Product Development Services | - | - | - | - | - | - | - | - | - | $77.00K | $97.00K | $158.00K | $107.00K | $289.00K | $885.00K | $411.00K | $320.00K | - | - | - |
| Royalties From Licensing Agreements | - | - | - | - | - | - | - | - | - | - | - | $11.21M | $276.00K | $339.00K | $491.00K | $-251.00K | $577.00K | - | - | - |
| Sales Of Branded Pharmaceutical Products | - | - | - | - | - | - | - | - | - | $14.31M | $11.04M | $7.52M | $15.76M | $12.41M | $10.63M | $14.00M | $17.54M | - | - | - |
| Sales Of Contract Manufactured Products | - | - | - | - | - | - | - | - | - | $3.00M | $3.60M | $6.30M | $2.19M | $7.80M | $5.80M | $2.64M | $5.50M | $6.40M | - | - |
| Sales Of Generic Pharmaceutical Products | - | - | - | - | - | - | - | - | - | $35.14M | $34.20M | $32.99M | $38.65M | $37.71M | $33.40M | $36.26M | $31.60M | - | - | - |
| Unapproved Products | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.40M | $4.70M | - | - | - |
| Performance Obligation From Prior Period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $16.70M | - | - | - |
ANI Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Sales of generic pharmaceutical products (65.53%), and Sales of rare disease pharmaceutical products (34.47%).
ANI Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| CANADA | $565.00K | - | - | - | - |
| UNITED STATES | $486.25M | - | - | - | - |
| Canada | - | $3.96M | $4.24M | $6.88M | - |
| United States | - | $312.43M | $211.89M | $199.66M | - |
| C | - | - | - | $5.59M | - |
| U | - | - | - | $202.88M | - |
ANI Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (99.88%), and CANADA (0.12%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $137.43M | $369.70M | $116.55M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| CANADA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Canada | - | - | - | $565.00K | $1.23M | $970.00K | $1.04M | $717.00K | $1.04M | $1.54M | $1.39M | $1.31M | $2.21M | $1.99M | - | - | - | - | - | - |
| United States | - | - | - | $106.22M | $93.00M | $82.85M | $72.81M | $63.76M | $59.89M | $48.23M | $46.58M | $50.03M | $52.14M | $50.90M | - | - | - | - | - | - |
| C | - | - | - | - | - | - | - | - | - | $961.00K | $1.04M | $1.19M | $973.00K | $885.00K | $2.19M | - | - | - | - | - |
| U | - | - | - | - | - | - | - | - | - | $51.10M | $47.58M | $53.33M | $56.28M | $52.09M | $46.28M | - | - | - | - | - |
ANI Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (100.00%).
ANI Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| PROC | Procaps Group | $409.92M | $118.41M |
| INCR | InterCure | $355.55M | $73.47M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
ANIP Revenue FAQ
What is ANI Pharmaceuticals’s yearly revenue?
ANI Pharmaceuticals's yearly revenue for 2023 was $486.82M, representing an increase of 53.87% compared to 2022. The company's yearly revenue for 2022 was $316.38M, representing an increase of 46.38% compared to 2021. ANIP's yearly revenue for 2021 was $216.14M, representing an increase of 3.67% compared to 2020.
What is ANI Pharmaceuticals’s quarterly revenue?
ANI Pharmaceuticals's quarterly revenue for Q2 2024 was $138.04M, a 0.44% increase from the previous quarter (Q1 2024), and a 18.44% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $137.43M, a 4.39% increase from the previous quarter (Q4 2023), and a 28.70% increase year-over-year (Q1 2023). ANIP's quarterly revenue for Q4 2023 was $131.65M, a -0.13% decrease from the previous quarter (Q3 2023), and a 39.71% increase year-over-year (Q4 2022).
What is ANI Pharmaceuticals’s revenue growth rate?
ANI Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 125.24%, and for the last 5 years (2019-2023) was 135.69%.
What are ANI Pharmaceuticals’s revenue streams?
ANI Pharmaceuticals's revenue streams in c 23 are Sales of generic pharmaceutical products, Sales of rare disease pharmaceutical products, and Sales of established brand pharmaceutical products. Sales of generic pharmaceutical products generated $269.45M in revenue, accounting 55.35% of the company's total revenue, up 28.24% year-over-year. Sales of rare disease pharmaceutical products generated $112.12M in revenue, accounting 23.03% of the company's total revenue, up 168.96% year-over-year. Sales of established brand pharmaceutical products generated $105.25M in revenue, accounting 21.62% of the company's total revenue, up 166.71% year-over-year.
What is ANI Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of ANI Pharmaceuticals was Sales of generic pharmaceutical products. This segment made a revenue of $269.45M, representing 55.35% of the company's total revenue.